{"disease":{"id":"spinal-muscular-atrophy-sma","name":"spinal muscular atrophy sma"},"drugs":{"marketed":[{"drug_id":"onasemnogene-abeparvovec-brve","indication_name":"Spinal Muscular Atrophy (SMA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Onasemnogene Abeparvovec-brve","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"SMN1 gene","drug_class":"Gene Therapy","quality_score":56,"revenue":null,"mechanism":"ITVISMA delivers a functional SMN1 gene using an AAV9 vector to promote SMN protein expression in motor neurons."},{"drug_id":"pf-06954522","indication_name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06954522","generic_name":"pf-06954522","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific target]","drug_class":"Small molecule inhibitor","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04174157","title":"Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06978985","title":"Adult SMA Research and Clinical Hub","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Newcastle-upon-Tyne Hospitals NHS Trust","has_results":false},{"nct_id":"NCT05115110","title":"A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07223489","title":"Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Medstar Health Research Institute","has_results":false},{"nct_id":"NCT05335876","title":"Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05354414","title":"Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT07287982","title":"A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT07208903","title":"Psychological Evaluation of the Parental Experience of Newborn Screening for Infantile Spinal Muscular Atrophy in the Grand Est and Nouvelle-Aquitaine Regions","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT06599606","title":"Ultrasonographic Muscle Assessment and Functional Scales in Spinal Muscular Atrophy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Istanbul University - Cerrahpasa","has_results":false},{"nct_id":"NCT07072676","title":"The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT07321977","title":"Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Institut de Myologie, France","has_results":false},{"nct_id":"NCT06363357","title":"The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients With Neuromuscular Disorder","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07356063","title":"Self-Efficacy Enhancement Using a Multicomponent Support Group for Caregivers of Children With DMD/SMA","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT07332702","title":"Long Read Analysis in Spinal Muscular Atrophy - LOREASI","phase":"NA","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT07488338","title":"HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Teachers College, Columbia University","has_results":false},{"nct_id":"NCT07336602","title":"Neuroproprioceptive Equine-Assisted Physiotherapy for Spinal Muscular Atrophy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Charles University, Czech Republic","has_results":false},{"nct_id":"NCT07265232","title":"Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Lantu Biopharma","has_results":false},{"nct_id":"NCT06648486","title":"Robot-assisted Training","phase":"NA","overall_status":"RECRUITING","enrollment_count":13,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT07254988","title":"Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders","phase":"NA","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Copenhagen","has_results":false},{"nct_id":"NCT02876094","title":"Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Hugh McMillan","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}